Home > PJ (current issue) > Letters | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 271 No 7266 p321
13 September 2003

This page
Reprint
Photocopy

   

PDF* 85K

Letters

  New Contract
  CPD
  Registartion exam
  IBS
  Storage temperature
  The Society


Letters to the Editor

New Contract

Minor ailments should be an essential service

From Mr A. Spooner, MRPharmS

I note that the recently proposed amendments to the control of entry regulations for England place a high priority on the desirability of increased competition and choice. The local primary care trust will have powers to administer this new regime and grant contracts where the criteria are fulfilled.

There are many new developments in community pharmacy, especially under the proposed new pharmacy contract and ad hoc pharmaceutical service developments in England. These new services may fall under the essential, enhanced or additional part of the new contract or could arise from the extension of prescribing rights. It is noticeable that many of these services may not be provided by all contractors for various reasons.

The reasons for the variation of ability to provide these services (and obtain the funds that flow from them) seem many and varied. Minor ailments, addiction, medicines management and other services are not currently being proposed within the essential part of the new contract but as additional/enhanced services. The ability of a pharmacist to get involved in these may be highly dependent on factors out of his control, such as access to training and funding. I understand that these will also be administered by PCTs.

It appears to me that there is scope for significant conflict of interest arising from the introduction of these two new regimes. On the one hand PCTs play a major role in deciding which contractors can enter into new service provision so as to differentiate themselves and extend choice and competition. They will then also determine new contract applications, in part, on the criteria of extended choice and competition. I suspect that this could lead to some rather difficult decisions where it might be impossible for PCTs to demonstrate equity to existing and proposed contractors. In my view, the solution to this potential problem might lie with the inclusion of the maximum number of services within the essential (if optional) part of any new contract — including minor ailment services, etc. Without this, it could be wise to separate the powers granted under the two regimes.

The non-inclusion of the minor ailment service within the core contract was disappointing. In light of recent reports of the success of pilot schemes in this area, illustrating not only a successful clinical, but also financial model, is it too late to renew arguments for inclusion of these in the essential part of the new contract?

Adrian Spooner
Solicitor and consultant,
London N3

Send your letter to The Editor

Next Topic (CPD)

  * PDF files on PJ Online require Acrobat Reader 4 or later.

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal